Zacks: Analysts Anticipate Gemphire Therapeutics Inc (GEMP) Will Announce Earnings of -$0.42 Per Share

Wall Street brokerages expect Gemphire Therapeutics Inc (NASDAQ:GEMP) to report ($0.42) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Gemphire Therapeutics’ earnings. Gemphire Therapeutics reported earnings per share of ($0.58) during the same quarter last year, which would indicate a positive year over year growth rate of 27.6%. The company is scheduled to report its next quarterly earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Gemphire Therapeutics will report full year earnings of ($1.59) per share for the current financial year. For the next year, analysts anticipate that the business will report earnings of ($3.55) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Gemphire Therapeutics.

Gemphire Therapeutics (NASDAQ:GEMP) last announced its quarterly earnings results on Friday, March 15th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15.

A number of research analysts have weighed in on the stock. Zacks Investment Research cut shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, April 11th. ValuEngine lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $14.90.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of Gemphire Therapeutics during the fourth quarter valued at approximately $27,000. Cary Street Partner Investment Advisory LLC bought a new stake in shares of Gemphire Therapeutics in the fourth quarter worth $212,000. Finally, BlackRock Inc. increased its stake in shares of Gemphire Therapeutics by 2,210.5% in the third quarter. BlackRock Inc. now owns 675,038 shares of the company’s stock worth $1,391,000 after buying an additional 645,822 shares during the last quarter. Institutional investors own 27.17% of the company’s stock.

GEMP stock traded up $0.03 during midday trading on Wednesday, reaching $1.36. 462 shares of the company’s stock traded hands, compared to its average volume of 41,526. The stock has a market cap of $18.98 million, a price-to-earnings ratio of -0.80 and a beta of 3.04. Gemphire Therapeutics has a fifty-two week low of $0.57 and a fifty-two week high of $11.43.

About Gemphire Therapeutics

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.

Recommended Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.